Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,477.16
(
-1.74%
)
US TECH 100
22,808.80
(
-0.62%
)
Dow Jones
45,960.11
(
0.00%
)
Brent Oil
104.74
(
4.04%
)
Bitcoin
66,620.99
(
-3.15%
)
News Focus
News Focus
Post# of 257295
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122815
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 232029

Wednesday, 05/06/2020 4:16:14 PM

Wednesday, May 06, 2020 4:16:14 PM

Post# of 257295
ENTA discontinues EDP-305 for PBC indication following phase-2 miss on primary endpoint:

https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Announces-Results-of-INTREPID-Study-of-EDP-305-for-the-Treatment-of-Primary-Biliary-Cholangitis/default.aspx

PBC is a small indication and EDP-305 is a bad drug, so ENTA’s discontinuing this program is entirely justifiable.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today